Adicet Bio, Inc. (ACET) · Nov 5, 2026 · Earnings
Miss — EPS loss $1.76 vs ~$1.58 consensus
Adicet Bio’s Q3 earnings missed the published EPS estimate, while the lupus program advanced mainly through previously disclosed milestones.
Adicet is a clinical-stage biotech building its story around prula-cel as a potential one-time treatment for lupus, while advancing ADI-212 in prostate cancer and an earlier in vivo CAR-T platform. The key lupus efficacy update—50% complete renal response and 54% DORIS remission at 12 months—was already disclosed on September 28, 2026, so this filing is mainly a quarterly financial check-in and milestone confirmation.
The quarter missed the published EPS bar. Adicet reported a $1.76 per-share loss versus a published Q3 consensus of approximately $1.58, making the clean earnings read a miss rather than an in-line result.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss per share (Income Statement) | $1.76 | $4.72 | $1.58 loss |
| Net loss (Income Statement) | $18.9M | $26.9M | |
| R&D expense (Income Statement) | $15.6M | $22.9M | |
| Cash and short-term investments (Balance Sheet) | $100.9M | $158.5M at Dec. 31, 2025 |
The business milestones are advancing, but this filing adds little surprise. The company says pivotal lupus-nephritis study startup is underway and plans FDA discussions about expanding into non-renal lupus; both were already telegraphed in the September clinical update. 〔0〕 The same is true of ADI-212, where the IND clearance, Fast Track designation, and planned first-quarter 2027 enrollment were already known. 〔1〕
Cash still supports the next development steps, not commercial independence. The $100.9 million cash balance is down from $158.5 million at year-end, but management says it should fund operating expenses into the second half of 2027. 〔2〕 That gives the company room to reach the next lupus and ADI-212 milestones without an immediately disclosed financing need, though the runway remains tied to execution and spending.
Bottom line: This was a modest earnings miss, while the clinical story remains intact but largely unchanged from the late-September disclosure. The filing slightly weakens the near-term read because the financial result fell short, but it does not materially alter Adicet’s development path. ⟧src: Prula-cel demonstrated positive safety and efficacy data in Phase 1 trial of patients with SLE with or without LN.⟧
Q4 FDA engagement; Q1 2027 12-month lupus data
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!